

From: (b) (6)
Sent: Fri, 28 Feb 2020 13:39:34 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Experimental vaccine for Covid-19

Please respond. Mention risk of enhancement

Begin forwarded message:

From: "William J. Buikema" (b) (6) >
Date: February 28, 2020 at 1:08:50 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Experimental vaccine for Covid-19

Dear Dr. Fauci,

I understand the need for the various stages of testing a new experimental vaccine, but in listening to you give a timeline for any new vaccine for the corona virus, it struck me that perhaps a modified approach might be considered. Why not allow early use of a vaccine that has passed a phase 1 safety testing, similar to what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe, why not allow its use in more at-risk people (elderly, smokers) before phase 2 trials are finished. It could also be helpful as with the Ebola vaccines to prevent transmission in hot spots of community acquired infections. There doesn't seem to be much downside compared to the potential for preventing many more deaths than was seen in the Ebola situation.

Sincerely yours,

Bill Buikema

William J. Buikema, PhD, Research Associate
Technical Director, DNA Sequencing & Genotyping Core
University of Chicago, KCB D 1230H&I
900 E 57th Street, Chicago, IL 60637
773-702-1088, cancer-seqbase.uchicago.edu